Latest Production News

Austral Resources Australia Ltd reported robust Q3 2025 copper production and secured $40 million in new capital, setting the stage for accelerated growth and ASX reinstatement.

Mount Hope Mining has raised $2.48 million through a placement and share purchase plan to accelerate drilling at its Mt Solitary gold prospect and the broader 7.5km gold corridor in the prolific Cobar Basin.

Elixir Energy is set to resume production testing at its Diona-1 well this quarter and prepare for the high-impact Lorelle-3 appraisal well drilling in January 2026, aiming to unlock significant gas resources in Queensland’s Taroom Trough.

Ioneer Ltd has enhanced the economics of its Rhyolite Ridge Lithium-Boron Project by cutting leach retention time, boosting lithium and boron production and improving key financial metrics with minimal capital cost increase.

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Nick Scali Limited reported a robust $62 million underlying profit for FY25, completed its UK acquisition equity raise, and announced key leadership changes as it eyes accelerated growth in FY26.

Whitebark Energy’s fresh petrophysical analysis reveals significant dry gas zones in its Warro Gas Field, boosting its commercial prospects and prompting a $750,000 capital raise to fast-track development.

HyTerra Ltd has successfully completed drilling and appraisal operations in Kansas, revealing elevated hydrogen and helium concentrations that reinforce the potential of its Nemaha Project. The company is advancing its US market presence with an OTCQB listing and strategic advisory appointments.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.